$1.320
-0.029 (-2.22%)終値時点
- 高値
- 1.390
- 始値
- 1.360
- 出来高加重平均価格
- 1.34
- 出来高
- 345.48K
- 時価総額
- —
- 安値
- 1.300
- 売買代金
- 461.79K
- EV/EBITDA（TTM）
- 0.00
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
AI分析 of NervGen Pharma Corp (NGEN)
売りNervgen Pharma Corp. is not a good buy right now. The current price is $1.35, which is significantly below the 52-week high of $6.30, indicating a steep decline of 78.40% year-to-date. Additionally, the RSI is at a very low 21.92, suggesting oversold conditions, but this may not be a strong enough signal to counteract the negative financial performance, including a net income loss of CAD 29,217,233 in Q2 2026. The main risk is the ongoing equity dilution from the recent public offering, which could further depress the stock price.
バリュエーション指標
イベントタイムライン
ニュース
2.010-12NewsfilterNervGen Launches RESTORE Study to Evaluate NVG-291
- 1.009-09Newsfilter
NervGen to Host Inaugural R&D Day Webcast
- 9.508-13Newsfilter
NervGen Reports Q2 2026 Financial Results and Progress Updates
8.506-11seekingalphaNervGen Pharma Shares Rise After Buy Rating from TD Cowen
- 8.505-26Newsfilter
NervGen's NVG-291 Shows Significant Improvement in Gait Quality
NGEN のよくある質問 — Alphio AI が回答
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair. It operates in the Healthcare sector.
Nervgen Pharma Corp. is not a good buy right now. The current price is $1.35, which is significantly below the 52-week high of $6.30, indicating a steep decline of 78.40% year-to-date. Additionally, the RSI is at a very low 21.92, suggesting oversold conditions, but this may not be a strong enough signal to counteract the negative financial performance, including a net income loss of CAD 29,217,233 in Q2 2026. The main risk is the ongoing equity dilution from the recent public offering, which could further depress the stock price.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。